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Neurofibromin knockdown in 
glioma cell lines is associated with 
changes in cytokine and chemokine 
secretion in vitro
Matthew D. Wood  1,3, Joydeep Mukherjee2 & Russell O. Pieper2
The neurofibromin-1 tumor suppressor gene (NF1) is altered in approximately 20% of sporadic 
glioblastoma (GBM) cases. NF1 deficient GBM frequently shows a mesenchymal gene expression 
signature, suggesting a relationship between NF1 status and the tumor microenvironment. To identify 
changes in the production of secreted cytokines/chemokines in NF1 deficient glioma, we applied 
cytokine arrays to conditioned media from a panel of three GBM cell lines after siRNA-mediated 
NF1 knockdown. We identified increased secretion of platelet-derived growth factor AA (PDGF-AA), 
chitinase-3-like protein 1 (CHI3L1), interleukin-8 (IL-8), and endoglin (ENG) in different subsets of these 
cell lines. Secretion was associated with induction of the corresponding messenger RNA, suggesting 
a mechanism involving transcriptional upregulation. By contrast, in non-transformed immortalized 
normal human astrocytes, PDGF-AA secretion was increased upon NF1 knockdown, while secreted 
CHI3L1, ENG, and IL-8 were reduced or unchanged. Analysis of The Cancer Genome Atlas confirmed 
a relationship between glioma NF1 status and ENG and CHI3L1 in tumor samples. Overall, this study 
identifies candidate changes in secreted proteins from NF1 deficient glioma cells that could influence 
the tumor microenvironment, and suggests a direct link between NF1 loss and increased tumor cell 
production of CHI3L1 and endoglin, two factors implicated in mesenchymal identity in glioblastoma.
Mutation in the NF1 gene cause neurofibromatosis type 1 (NF1), which predisposes patients to the development 
of peripheral and central nervous system (CNS) tumors, along with several other clinical manifestations. The 
most common CNS neoplasm in the setting of NF1 is a WHO grade I pilocytic astrocytoma. However, NF1 
patients are also predisposed to developing higher-grade infiltrating gliomas1. In 2008, The Cancer Genome Atlas 
(TCGA) analysis of glioblastoma (GBM) revealed NF1 mutations or other alterations in approximately 20% of 
sporadic GBM, i.e. in patients without NF12. Since this discovery, there has been considerable interest in identi-
fying a role for NF1 alterations in sporadic GBM.
NF1 encodes neurofibromin, a GTPase activating protein that serves as a negative regulator of Ras signaling 
and Ras-associated downstream signaling pathways3. In NF1, several tumor types have been shown to have inac-
tivation of the wild-type NF1 allele, supporting the notion that NF1 is a bona fide tumor suppressor gene4,5. In 
sporadic glioblastoma, a post-translational mechanism for neurofibromin degradation has also been described6. 
Compared to diffusely infiltrating gliomas with intact NF1, lower grade gliomas with NF1 alteration have a worse 
prognosis, while GBM with NF1 alteration has a similar clinical outcome to cases without NF1 alterations7.
Gene expression profiling of GBM has shown that NF1 alterations are associated with a so-called mesenchy-
mal gene expression pattern8,9. Recent data suggest that the mesenchymal gene expression pattern may reflect 
features in the tumor microenvironment, rather than an intrinsic feature of the neoplastic cells10,11. This asso-
ciation between NF1 loss and the mesenchymal gene expression pattern suggests a direct role for GBM NF1 
status influencing the tumor microenvironment. Supporting this possibility, numerous inflammatory media-
tors–including some factors that are regulated by signaling pathways downstream of Ras, such as MEK-ERK 
and Akt–have been implicated in GBM initiation and progression12. Tumor NF1 status strongly predicts the 
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presence of tumor-infiltrating lymphocytes, and a recent mechanistic study showed that conditioned media from 
NF1-deficient glioma cells increases macrophage recruitment in vitro10,13.
In order to study the role of NF1 as a mediator of the tumor microenvironment in GBM, we examined how 
NF1 loss influences secreted factors from neoplastic cells by applying glioma cell line conditioned media to 
cytokine arrays. Surprisingly, only a few recurrent changes were identified across a panel of three glioma cell 
lines. Here, we report that neurofibromin knockdown was associated with increases in expression and secretion 
of platelet-derived growth factor AA (PDGF-AA) and interleukin-8 (IL-8), two factors that influence tumor angi-
ogenesis and inflammatory cell recruitment, and chitinase-3-like protein 1 (CHI3L1) and endoglin (ENG), two 
markers of the mesenchymal gene expression subclass in GBM. Correlation of our in vitro finding with TCGA 
data suggests an in vivo association between NF1 status and tumor production of CHI3L1 and ENG, supporting 
an association between NF1 and mesenchymal identity in human GBM samples.
Methods
Cell lines. Normal human astrocytes immortalized by expression of the catalytic subunit of telomerase 
and the E6/E7 oncoproteins were generated in our laboratory and have been previously described14. T98G 
cells were obtained from American Type Culture Collection (ATCC). SF268 and SF295 cells were provided 
by the University of California San Francisco (UCSF) Brain Tumor Research Center Tissue Core. Media was 
obtained from the UCSF Cell Culture Facility. Cell lines were maintained at 37 °C in a humidified 5% CO2 incu-
bator in high glucose Dulbecco’s modified Eagles media (DMEM-H21) supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin, and 1% fungizone. All cell lines were negative for mycoplasma by 
PCR analysis (forward primer GPO3 5′-GGGAGCAAACAGGATTAGATACCCT-3′, reverse primer MGSO 
5′-TGCACCATCTGTCACTCTGTTAACCTC-3′)15. Cell line identities were confirmed by short tandem repeat 
analysis.
siRNA Transfection. ON-TARGETplus siRNA SMARTpools were purchased from Dharmacon (Lafayette, 
CO) and reconstituted according to the manufacturer’s instructions. Cells were seeded at 0.1 × 106 cells per well 
in triplicate wells of 6-well tissue culture plates in DMEM-H21 10% FBS without antibiotics. Twenty-four hours 
later, cells were transfected with 20 nM siControl (product number D-001206-14-05) or siNF1 (product num-
ber L-003916-00-005) SMARTpools, using DharmaFECT 1 reagent according to the manufacturer’s protocol. 
Eighteen hours after transfection, the transfection medium was replaced with DMEM 10% FBS with antibiotics, 
and cells were incubated for a total of 72 hours from initial transfection before harvesting the conditioned media 
for ELISA, and the cells for total RNA and protein extraction.
Western Blotting. Cells were harvested by washing once with ice-cold phosphate buffered saline (PBS), 
then scraping into ice-cold PBS, followed by centrifugation for 3 minutes at 200 × g and resuspension in lysis 
buffer (20 mM Tris-HCL pH 7.4, 100 mM NaCl, 300 mM sucrose, 6 mM MgCl2, 1 mM EGTA, 0.5% Triton 
X-100) supplemented with 1 × PhosStop/protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Protein was 
extracted by overnight incubation at 4 °C with gentle rotation, followed by clarifying lysates by centrifugation 
at 16,000 × g at 4 °C for 10 minutes. Protein concentrations were determined by DC Protein Assay (Bio-Rad 
Laboratories, Hercules, CA). Total protein (40 ng) in 1 × loading dye with 0.1 M DTT was fractionated on Novex 
4%–20% Tris-Glycine gels (Invitrogen, Carlsbad, CA) for 2 hours at 100 volts, then transferred to Immuno-Blot 
PVDF membranes (Bio-Rad Laboratories) overnight at 4 °C for 18 hours in transfer buffer without methanol. 
Membranes were blocked for 1 hour in 5% nonfat milk (Bio-Rad Laboratories) suspended in 1 × tris-buffered 
saline with 0.05% Tween-20 (TBST; Teknova, Hollister, CA). Primary antibodies were diluted in 1 × TBST 
5% milk or 5% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) and applied for 18 hours at 4 °C 
with gentle rocking. Membranes were washed 3 times quickly and then 3 times for 15 minutes in 1 × TBST at 
room temperature before applying HRP-conjugated secondary antibodies diluted 1:20,000 in 5% milk TBST 
(anti-mouse HRP sc-2031 and anti-rabbit HRP sc-2030 from Santa Cruz Biotechnologies, Dallas, TX). After 
repeating the 1 × TBST wash steps, bands were detected by ECL reagent (GE Healthcare, Chicago, IL). Primary 
antibodies were obtained from Cell Signaling Technology (Danvers, MA), ERK #9102, diluted 1:2000 in 5% BSA 
1 × TBST, phospho-ERK #9106, diluted 1:2000 in 5% milk 1 × TBST, and GAPDH #2118, diluted 1:5000 in 5% 
BSA 1 × TBST, or Santa Cruz Biotechnologies, NF1 H-12 mouse monoclonal sc-376886 diluted 1:100 in 5% milk 
1 × TBST.
Cytokine Array. Cells were transfected as described in the siRNA protocol, except the medium was replaced 
with serum- and antibiotic-free DMEM-H21 for the final 24 hours of the incubation. Medium from 3 wells was 
pooled, clarified by centrifugation at 200 × g at 4 °C, and immediately applied to Proteome Profiler Human XL 
cytokine arrays according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN). Cytokine array 
signal was detected at multiple exposure times ranging from 15 seconds to 10 minutes. Film was scanned using an 
Epson Perfection V78 Pro transmission mode scanner and Epson SilverFast software. Signal levels were measured 
using ImageJ software with the Protein Array Analyzer plugin16. Values from duplicate spots were averaged, and 
the relative signal was calculated in siNF1 treated sample, compared to siControl treated cells.
Quantitative RT-PCR. When cells were harvested for protein extraction, an aliquot of the PBS resuspended 
cells was removed, centrifuged at 300 × g for 5 minutes, and cell pellets were stored at −80 °C. Total RNA was 
extracted with RNEasy Mini Kit (Qiagen, Hilden, Germany) and cDNA was synthesized from 1000 ng of total 
RNA in a 40 μL reaction using Supertscript II Reverse Transriptase (Invitrogen) and oligo-dT primers from 
Integrated DNA Technologies (Coralville, IA). 1 μL of the cDNA reaction was used for quantitative RT-PCR using 
the Rotor-Gene System (Qiagen) and the following qPCR primers obtained from Integrated DNA Technologies: 
HPRT1 (forward 5′-GGTCAGGCAGTATAATCCAAAGA-3′, reverse 5′-GAAGCGGTCAAGGGCATCT-3′), NF1 
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(forward 5′-GGACTCTAAGATCAACACCCTG-3′, reverse 5′-CACCACACTCTGCACAATTCCAT-3′, refer-
ence17), CHI3L1 (forward 5′-GTGAAGGCGTCTCAAACAGG-3′, reverse 5′-GAAGCGGTCAAGGGCATCT-3′), 
PDGFA (forward 5′-GCAAGACCAGGACGGTCATTT-3′, reverse 5′-GGCACTTGACACTGCTCGT-3′), 
CXCL8/IL8 (forward 5′-GCTCTGTGTGAAGGTGCAGT-3′, reverse 5′-ACTTCTCCACAACCCTCTGC-3′), 
and ENG (forward 5′-TGCACTTGGCCTACAATTCCA-3′, reverse 5′-AGCTGCCCACTCAAGGATCT-3′). 
Some qPCR primers were picked using the PrimerBank qPCR primer database18. Reaction conditions were as 
follows: 95 °C for 10 minutes, 40 cycles of 95 °C 10 seconds, 54 °C 15 seconds, and 72 °C 20 seconds). Differences in 
RNA expression between siNF1 and siControl treated cells was determined by the ΔΔCt method19.
ELISA. Medium from three wells of siRNA treated cells was pooled and clarified by centrifugation at 200 × g 
for 5 minutes at 4 °C, and aliquots were stored at −20 °C. ELISA for secreted factors was performed using kits, 
according to the manufacturer’s instructions (CHI3L1 product MC3L10 from R&D Systems, PDGF-AA product 
ab100622 from Abcam [Cambridge, United Kingdom], endoglin product DNDG00 from R&D Systems, and IL-8 
product D8000C from R&D Systems). Conditioned medium from three independent transfections was analyzed.
TCGA Analysis. Data were retrieved from the cBioPortal database in August 2017. Glioblastoma TCGA data 
for 291 complete samples was queried for mutations, copy number alterations (GISTIC), and RNA expression 
z-scores (RNASeq V2 RSEM, threshold +/− 2) using NF1, CHI3L1, PDGFA, ENG, and CXCL8 as the input gene 
set2. Overall, 147 cases had RNA expression data. NF1-altered cases (mutation, mRNA downregulation > 2-fold, 
or homozygous deletion, N = 12) were compared to cases with no NF1 alteration (N = 129). Cases with NF1 
mRNA upregulation (i.e. mRNA z-score > 2, N = 6) were excluded from the analysis.
Statistical Analysis. Data analysis was performed using GraphPad Prism software. Graphs of ELISA and 
qPCR data show the mean ± standard deviation of three independent experiments. Significance levels are from 
paired bidirectional T-tests, with *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical tests on the qPCR data for 
each cell line were adjusted for multiple comparisons (i.e. 4 comparisons for each cell line). Gene expression 
z-scores from TCGA were analyzed by Mann-Whitney test, also using GraphPad software.
Data Availability Statement. All data generated or analyzed during this study are included in this pub-
lished article, and its Supplementary Information files.
Results
To establish conditions for knocking down neurofibromin protein, we treated three glioblastoma cell lines (T98G, 
SF268, and SF295) and non-transformed immortalized normal human astrocytes (NHA-E6/E7-hTert) with a 
SMARTpool of four siRNA constructs targeting the NF1 transcript (siNF1) optimized for target specificity, or a 
nontargeting SMARTpool control (siControl). According to the canSAR database, T98G, SF295, and SF268 do 
not have any NF1 mutations, and all of the cell lines express neurofibromin protein, therefore the cell lines that 
we selected for this study are highly likely to be neurofibromin proficient at baseline20,21. Seventy-two hours after 
the siRNA transfection, we observed a statistically significant reduction in NF1 messenger RNA across all four 
cell lines, and an associated reduction in detectable neurofibromin protein by Western blot (Fig. 1A,B; cropped 
images are shown to conserve space, and the expanded Western blots and additional information on the Western 
blotting methods are provided in Supplemental Figure S1). This was associated with a detectable increase in ERK 
phosphorylation across all cell lines, as assessed by Western blot with phospho-specific antibodies (Fig. 1A). 
Upon quantitation, this trend this did not reach statistical significance due to high variability between replicates 
(Fig. 1C). None of the cell lines showed induction of p21 (data not shown), a senescence marker that can be 
induced by strong NF1 knockdown as a result of oncogene-induced senescence in some glioma cell lines22.
We collected conditioned media from siControl or siNF1 transfected cells and applied the media to protein 
arrays that detect 105 human cytokines and chemokines (Fig. 2A). An example of the data generated by this anal-
ysis is shown in Fig. 2B,C for T98G cells, and the complete findings are summarized in Fig. 2D and Supplemental 
Figure S2. Quantitation of the relative signal intensity of siNF1 versus siControl conditioned medium showed a 
greater than 2-fold increase in secreted PDGF-AA in T98G, SF295, and NHA-E6/E7-hTert cell lines. Secreted 
CHI3L1 was increased by 7-fold in T98G and by 1.2-fold in SF295. Secreted IL-8 was increased by 2.5-fold in 
SF268 cells, and by 1.6-fold in SF295 cells. Secreted ENG was increased only in T98G cells, by 2.8-fold. The 
cytokine array results show that under in vitro conditions, knockdown of neurofibromin protein is associated 
with relatively few changes in secreted cytokines and chemokines, with a few common alterations in secreted 
proteins across the examined glioma cell lines.
To confirm the cytokine array findings, we tested clarified conditioned media from an independent set of 
triplicate samples of conditioned media from siControl or siNF1 treated cells by ELISA. We analyzed all four cell 
lines for changes in secreted CHIL3L1, PDGF-AA, IL-8, and ENG, since these were the most consistently and/or 
significantly altered factors identified by the cytokine array analysis. The measured secreted cytokine values are 
listed in Table 1, and relative changes are shown in Fig. 3 and described here. Consistent with the cytokine array 
results, we detected an increase in secreted PDGF-AA in NF1 deficient T98G, SF295, and NHA-E6/E7-hTert cells, 
while secreted PDGF-AA was unchanged in SF268 (Fig. 3A). Also consistent with the cytokine array results, we 
observed increased secreted CHI3L1 from siNF1 transfected T98G cells, and an increase in secreted CHI3L1 
from siNF1 transfected SF295 cells above a high baseline level of secretion in the control condition (Fig. 3B, and 
Table 1). Secreted CHI3L1 was reduced by siNF1 treatment in NHA-E6/E7-hTert (Fig. 3B), and was not detect-
able in SF268 conditioned media under either siRNA condition. Secreted ENG was increased in T98G cells and 
unchanged in NHA-E6/E7-hTert, but was not detected in SF268 or SF295 cells (Fig. 3C). ELISA for IL-8 was com-
plicated by high inter-replicate variability in the absolute measured IL-8 levels, possibly related to storage of the 
conditioned media, therefore the measured values in Table 1 are from 2 (rather than 3) experimental replicates. 
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However, when the IL-8 levels were expressed as a ratio of siNF1 to siControl levels across all three replicates, 
there was a consistent induction of secreted IL-8 in T98G, SF268, and SF295 cells, while in NHA-E6/E7-hTert the 
secreted IL-8 level was significantly reduced (Fig. 3D), closely paralleling the findings from the cytokine arrays. 
Taken together, the ELISA data confirm the cytokine array findings and implicate PDGF-AA, CHI3L1, IL-8, and 
ENG as secreted factors under negative regulatory control by neurofibromin in a subset of glial tumor cell lines 
in vitro.
To determine whether there is transcriptional upregulation of the factors that we identified in the cytokine 
arrays and ELISA, we performed quantitative RT-PCR for CHI3L1, PDGFA, ENG and CXCL8/IL8 on all four 
cell lines transfected with siNF1 versus control siRNA (Fig. 4). In agreement with the ELISA data where secreted 
cytokines/chemokines were increased, we identified transcriptional upregulation of the following genes upon 
NF1 knockdown: PDGFA in NHA-E6/E7-hTert, T98G, and SF295 cells; CHI3L1 in T98G and SF295 cells; ENG in 
T98G cells, and CXCL8/IL8 in T98G, SF268, and SF295 cells. Also consistent with the reductions in secreted pro-
tein levels on ELISA, we observed a trend towards reduced CHI3L1 and CXCL8/IL8 in NHA-E6/E7-hTert cells, 
though this did not reach statistical significance. We observed transcriptional changes in some factors that were 
not detectable by ELSA in the same cell line, specifically induction of ENG in SF268 and SF295 and reduction of 
CHI3L1 in SF268, which may reflect the higher sensitivity of quantitative RT-PCR. In only two instances, signif-
icant changes in the mRNA transcript levels were observed without a corresponding change in secreted protein: 
PDGFA was induced in SF268 without increased secretion, and ENG was induced in NHA-E6/E7-hTert without 
increased secretion. With these two exceptions, the qPCR data was fully concordant with the ELISA results, 
suggesting that neurofibromin loss could influence the glioma cell secreted protein profile through regulation of 
transcription. A summary of the significant changes across three testing modalities (i.e. cytokine array, ELISA, 
and quantitative RT-PCR) is provided as Supplemental Figure S3.
We turned to The Cancer Genome Atlas (TCGA) data to determine the in vivo relevance of our findings in 
human tumor samples. TCGA glioblastoma cases were classified into two categories: those with an alteration of 
the NF1 gene (i.e. mutation, deletion, or mRNA downregulation, N = 12) or no evidence of a deleterious NF1 
alteration (N = 129). Cases in the NF1-altered group showed a significantly lower NF1 mRNA z-score compared 
to the NF1 intact group, confirming that these categories differ in their levels of NF1 mRNA expression (Fig. 5A). 
The NF1-altered group of tumors showed significantly higher expression of CHI3L1 and ENG (Fig. 5B,C), while 
the PDGFA and CXCL8/IL8 RNA levels were not significantly altered between the two groups (Supplemental 
Figure 1. Confirmation of neurofibromin knockdown by Western blot (A) and quantitative RT-PCR (B) in 
four cell lines used in the study. All cell lines showed an increase in phosphorylated ERK protein by Western 
blot (A). (C) Quantitation of the increased phospho-ERK signal did not achieve statistical significance (values 
are mean +/− standard deviation of 3 independent replicates for NHA, T98G, and SF268, and of 2 replicates for 
SF295; in a third SF295 assay, P-Erk levels were too low for reliable quantitation).
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Figure S4). Taken together with the in vitro findings, these data raise the possibility an in vivo link between loss of 
neurofibromin and increased expression of CHI3L1 and ENG, two factors that could reflect GBM mesenchymal 
identity.
Discussion
Mutations and structural alterations of the NF1 tumor suppressor gene are common in GBM, but the significance of 
these genetic alterations for tumor behavior is not fully understood. NF1 alterations are enriched in the mesenchy-
mal gene expression subgroup of GBM, and recent studies suggest that this gene expression subclass is influenced 
at least partly by the tumor microenvironment11,23. This raises the question of how neurofibromin deficiency in 
neoplastic astrocytes could influence the microenvironment. To begin to understand this role for NF1 loss in GBM, 
we performed an in vitro study of glioma cell lines and compared the results to non-transformed immortalized 
Figure 2. Human cytokine array results from conditioned media of four cell lines after neurofibromin 
knockdown. (A) Reference key for cytokine array, adapted from the manufacturer’s information. (B) Complete 
array images and (C) quantitation of resulting data from siControl and siNF1 treated T98G cells. Quantitation 
was performed on a 2 minute exposure, except for CHI3L1 (8 minute exposure). (D) Summary of array data for 
all factors with changes upon siNF1 treatment. Only factors with at least 2-fold increased expression upon NF1 
knockdown are pictured, other changes are noted by text only. Complete array images and quantitations are 
provided in the supplementary information.
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normal human astrocytes. These NHA-E6/E7-hTert cells have been extensively studied, grow rapidly, and are readily 
transfected, circumventing some of the technical limitations of non-immortalized primary human astrocytes. NF1 
knockdown under our experimental conditions resulted in increased secretion of surprisingly few cytokines and 
chemokines in the glioma cell lines. We found evidence for an association between NF1 loss and transcriptional 
upregulation and secretion of CHI3L1 and ENG, two markers of mesenchymal lineage cell types that are expressed 
Factor Cell Line
Mean ± SD (pg/mL)
siCon siNF1
PDGF-AA
T98G 1691 ± 369 5035 ± 468
SF268 1439 ± 422 1327 ± 255
SF295 797 ± 185 2995 ± 751
NHA E6/E7 hTert 3014 ± 1246 7697 ± 707
CHI3L1
T98G 133 ± 69 640 ± 305
SF268 Not detected Not detected
SF295 13180 ± 1919 20146 ± 1322
NHA E6/E7 hTert 780 ± 308 273 ± 80
ENG
T98G 455 ± 140 591 ± 125
SF268 Not detected Not detected
SF295 Not detected Not detected
NHA E6/E7 hTert 336 ± 96 353 ± 107
IL-8
T98G 1747 ± 441 2438 ± 537
SF268 2179 ± 180 4615 ± 467
SF295 3076 ± 479 7702 ± 481
NHA E6/E7 hTert 4307 ± 181 2257 ± 415
Table 1. Measured concentrations of secreted PDGF-AA, CHI3L1, ENG, and IL-8 in conditioned media 
from siControl and siNF1 treated cell lines. Values are from three independent replicates, except for IL-8 (2 
replicates).
Figure 3. ELISA confirmation of factors increased on cytokine array for (A) secreted PDGF-AA, (B) secreted 
CHI3L1, (C) secreted ENG, and (D) secreted IL-8. Graphs represent the mean fold-change +/− standard 
deviation of three replicates. N.D. indicates that the factor was not detected.
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in a subset of GBM. We also identified transcriptional upregulation of PDGFA and CXCL8/IL8 and corresponding 
increased secretion of PDGF-AA and IL-8, two factors that can influence tumor inflammatory cell content and vas-
cular proliferation. Interestingly, we observed that in NHA-E6/E7-hTert cells, secreted IL-8 and CHI3L1 levels were 
reduced by NF1 knockdown, and secreted ENG was unchanged, suggesting that the effects of NF1 loss on CHI3L1, 
IL-8, and ENG secretion is different in transformed versus non-transformed astrocytes. NHA-E6/E7-hTert cells are, 
however, different from primary astrocytes, so further study is required to confirm this relationship.
Figure 4. Quantitative RT-PCR for transcriptional induction or repression of the NF1 regulated factors that 
were identified by cytokine array in siNF1-treated cell lines.
Figure 5. TCGA analysis of gene expression levels in NF1 altered GBM. Z-scores of the mRNA expression 
values for (A) NF1, (B) CHI3L1, and (C) ENG are shown.
www.nature.com/scientificreports/
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Chitinase-3-like protein 1 (CHI3L1; also called YKL-40) is a secreted chitin-binding glycoprotein that lacks 
chitinase activity24. CHI3L1 is expressed in a subset of gliomas, and an in vitro study has implicated CHI3L1 in 
promoting glioma cell invasion and survival25. A number of immune and mesenchymal cell types express CHI3L1 
during cellular differentiation or pathologic inflammatory conditions, but astrocytes have also been shown to 
produce CHI3L1 in vivo under the control of proinflammatory cytokines produced by macrophages, and in the 
setting of glial neoplasms26,27. Interestingly, CHI3L1 is an immunophenotypic marker of the mesenchymal gene 
expression subclass of GBM28. This study is the first suggestion, to our knowledge, of a direct link between NF1 
loss in glioma and production of CHI3L1 by neoplastic cells. Since CHI3L1 is implicated as a driver of some 
aspects of mesenchymal behavior in GBM, our study raises the possibility of a mechanistic link between NF1 and 
mesenchymal phenotype, mediated in part by CHI3L1 that is produced by the neoplastic glioma cells.
Endoglin (ENG; also called CD105) is a transmembrane protein component of the transforming growth fac-
tor beta (TGF-β) receptor complex that is expressed in approximately 40% of primary glioblastoma samples, but 
not in secondary GBM or normal brain29. ENG expression is controlled, at least in part, by TGF-β signaling and 
contributes to mesodermal differentiation in primary GBM30. As with CHI3L1, the results from our study raise 
the possibility of a direct link between NF1 loss and mesenchymal identity in vitro. Interestingly, the relationship 
between GBM NF1 status and increased expression of CHI3L1 and ENG was preserved in TCGA data, suggest-
ing that there is in vivo relevance for these findings. The mechanistic significance of secreted ENG in glioma 
is not clear. In mouse models of skin carcinogenesis, membrane-associated ENG suppresses H-Ras mediated 
transformation31. Shedding of the membrane-associated ENG is associated with increased TGF-β signaling and 
progression to spindle morphology in squamous cell carcinoma32. The increase in secreted ENG that we observed 
in NF1-deficient T98G cells might therefore reflect an increase in TGF-β signaling, a pathway that is implicated 
in mesenchymal transition in GBM33.
Interleukin-8 is expressed in GBM and mostly has pro-angiogenic effects, but is also implicated in neutro-
phil chemotaxis and autocrine growth-promoting effects34. In our study, NF1 knockdown was associated with 
increased transcription and secretion of IL-8 in 2 of 3 glioma cell lines. However, we did not observe a relation-
ship between GBM NF1 status and CXCL8/IL8 mRNA levels in vivo, as assessed by TCGA analysis. Similarly, 
although we identified increased secretion of PDGF-AA in two glioma cell lines as well as immortalized normal 
human astrocytes upon NF1 knockdown, this relationship was not preserved in the TCGA data.
Our study has a number of limitations. First, we assessed a small number of cell lines using in vitro approaches, 
so our findings do not reflect the complexity of the tumor/microenvironment interaction that occurs in vivo. 
Second, we did not seek to define the precise mechanisms by which NF1 deficiency leads to increased secretion 
of such a small number of cytokines and chemokines, beyond suggesting that part of the mechanism is by tran-
scriptional upregulation. Further studies are required to define a signaling pathway responsible for induction of 
the factors that we found in this work. Third, some of the relationships identified in our study are not supported 
by in vivo data from TCGA – specifically for PDGF-AA and IL-8. Part of this limitation can be attributed to tissue 
culture artifacts, but it is also likely related to the small number of NF1-deficient GBM samples in the database. 
Finally, although the siRNA constructs that we used are modified for maximum specificity, rescue experiments 
would be required to prove the findings are due to an on-target (i.e. neurofibromin-specific) effect. However, we 
note that the siRNA constructs that we employed have been validated and used in previous studies, we identified 
commonalities across different cell lines, and we used TCGA data to support the findings35,36. Therefore, we con-
sider it unlikely for our findings to be solely an off-target phenomenon.
As clinical next-generation sequencing for brain tumors becomes more common, more NF1-altered gliomas 
will be identified, and the identification of such tumors will be critical for further study. Our data suggest that NF1 
loss could directly alter the regulation and expression of factors that contribute to cellular mesenchymal identity 
and the tumor/microenvironment interaction.
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